Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Organogenesis Holdings Inc.ORGO · Entity 6275 | Vice President, Strategy | March 01, 2026 | March 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Organogenesis Holdings Inc.
Report date March 01, 2026 · Filed March 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 275,524 |
Reported balance
After 2026-03-01 transaction · row 1
1 source rowRow 1 · 2026-03-01 · Tax withholding · Disposed 700 · Balance 275,524 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2026 Filed Mar 3, 2026 16:55 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 700 | $3.21 | $2,247.00 |
DisclosureSEC source: 0002064832-26-000093 · form4.xml · nonDerivative · entry 1 Cavorsi Robert · CIK 0002020983 · Vice President, Strategy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 275,524 Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 17:28 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantStock Option (Right to Buy) · Derivative | 53,452 | $0.00 Strike: $3.84 | $0.00 |
DisclosureSEC source: 0002064832-26-000061 · form4.xml · derivative · entry 4 Cavorsi Robert · CIK 0002020983 · Vice President, Strategy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,452 Underlying: Class A Common Stock · 53,452 shares Expires 2036-02-18 F3 · derivative.exercise_date: The option becomes exercisable in equal annual installments over four years beginning February 15, 2026. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 17:28 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 5,432 | $3.84 | $20,858.88 |
DisclosureSEC source: 0002064832-26-000061 · form4.xml · nonDerivative · entry 3 Cavorsi Robert · CIK 0002020983 · Vice President, Strategy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 276,115 Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 17:28 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 16,290 | $0.00 | $0.00 |
DisclosureSEC source: 0002064832-26-000061 · form4.xml · nonDerivative · entry 2 Cavorsi Robert · CIK 0002020983 · Vice President, Strategy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 281,547 F2 · shares: Shares issued pursuant to the vesting and settlement of a performance share award granted in 2025 based on the achievement of certain performance milestones. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 17:28 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 93,750 | $0.00 | $0.00 |
DisclosureSEC source: 0002064832-26-000061 · form4.xml · nonDerivative · entry 1 Cavorsi Robert · CIK 0002020983 · Vice President, Strategy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 265,257 F1 · shares: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 15, 2026. Read SEC document |
| February 18, 2026 Filed Mar 3, 2026 16:34 UTC Amendment | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 5,487 | $3.84 | $21,070.08 |
DisclosureSEC source: 0002064832-26-000087 · form4a.xml · nonDerivative · entry 2 Cavorsi Robert · CIK 0002020983 · Vice President, Strategy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 276,224 F1 · shares: This Form 4 is being filed as an amendment to the Form 4 originally filed on February 20, 2026, to correct the number of shares reported as acquired upon the vesting and settlement of a performance share award and the number of shares reported as withheld in satisfaction of tax obligations in connection with such award. No other changes have been made to the original filing. Read SEC document |
| February 18, 2026 Filed Mar 3, 2026 16:34 UTC Amendment | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 16,454 | $0.00 | $0.00 |
DisclosureSEC source: 0002064832-26-000087 · form4a.xml · nonDerivative · entry 1 Cavorsi Robert · CIK 0002020983 · Vice President, Strategy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 281,711 F1 · shares: This Form 4 is being filed as an amendment to the Form 4 originally filed on February 20, 2026, to correct the number of shares reported as acquired upon the vesting and settlement of a performance share award and the number of shares reported as withheld in satisfaction of tax obligations in connection with such award. No other changes have been made to the original filing. Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 16:37 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 5,442 | $3.73 | $20,298.66 |
DisclosureSEC source: 0002064832-26-000029 · form4.xml · nonDerivative · entry 3 Cavorsi Robert · CIK 0002020983 · Vice President, Strategy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 171,507 Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 16:37 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 5,549 | $3.73 | $20,697.77 |
DisclosureSEC source: 0002064832-26-000029 · form4.xml · nonDerivative · entry 2 Cavorsi Robert · CIK 0002020983 · Vice President, Strategy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 176,949 Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 16:37 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 6,667 | $3.73 | $24,867.91 |
DisclosureSEC source: 0002064832-26-000029 · form4.xml · nonDerivative · entry 1 Cavorsi Robert · CIK 0002020983 · Vice President, Strategy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 182,498 Read SEC document |
| July 16, 2025 Filed Jul 18, 2025 16:13 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 360 | $4.47 | $1,607.40 |
DisclosureSEC source: 0001062993-25-012995 · form4.xml · nonDerivative · entry 1 Cavorsi Robert · CIK 0002020983 · Vice President, Strategy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 189,165 Read SEC document |
| March 09, 2025 Filed Mar 12, 2025 16:29 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 61 | $5.16 | $314.76 |
DisclosureSEC source: 0001062993-25-005250 · form4.xml · nonDerivative · entry 2 Cavorsi Robert · CIK 0002020983 · Vice President, Strategy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 189,525 Read SEC document |
| March 09, 2025 Filed Mar 12, 2025 16:29 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 210 | $5.16 | $1,083.60 |
DisclosureSEC source: 0001062993-25-005250 · form4.xml · nonDerivative · entry 1 Cavorsi Robert · CIK 0002020983 · Vice President, Strategy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 189,586 Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 17:01 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 667 | $6.21 | $4,142.07 |
DisclosureSEC source: 0001062993-25-004351 · form4.xml · nonDerivative · entry 1 Cavorsi Robert · CIK 0002020983 · Vice President, Strategy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 189,796 Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 17:55 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantStock Option (Right to Buy) · Derivative | 63,830 | $0.00 Strike: $3.53 | $0.00 |
DisclosureSEC source: 0001062993-25-003235 · form4.xml · derivative · entry 2 Cavorsi Robert · CIK 0002020983 · Vice President, Strategy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,830 Underlying: Class A Common Stock · 63,830 shares Expires 2035-02-19 F2 · derivative.exercise_date: The option becomes exercisable in equal annual installments over four years beginning February 15, 2025. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 17:55 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 61,705 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-003235 · form4.xml · nonDerivative · entry 1 Cavorsi Robert · CIK 0002020983 · Vice President, Strategy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 190,463 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 15, 2025. Read SEC document |
| February 15, 2025 Filed Feb 19, 2025 19:20 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 6,008 | $3.70 | $22,229.60 |
DisclosureSEC source: 0001062993-25-002940 · form4.xml · nonDerivative · entry 2 Cavorsi Robert · CIK 0002020983 · Vice President, Strategy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 128,758 Read SEC document |
| February 15, 2025 Filed Feb 19, 2025 19:20 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 5,000 | $3.70 | $18,500.00 |
DisclosureSEC source: 0001062993-25-002940 · form4.xml · nonDerivative · entry 1 Cavorsi Robert · CIK 0002020983 · Vice President, Strategy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 134,766 Read SEC document |
| July 16, 2024 Filed Jul 18, 2024 17:03 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 317 | $3.09 | $979.53 |
DisclosureSEC source: 0001062993-24-013923 · form4.xml · nonDerivative · entry 1 Cavorsi Robert · CIK 0002020983 · Vice President, Strategy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 139,766 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.